Eligibility
Inclusion:
- "Definite" or "Probable" ALS according to the Revised El Escorial criteria (Airlie
House)
- ALS severity grade 1 or 2 according to the Japan ALS severity classification.
- ALSFRS-R scores of 2 or more for all items, with scores of 4 for all breathing-
related items (i.e., dyspnea, orthopnea, respiratory insufficiency).
- Within 2 years of ALS onset.
- %FVC of 80% or more.
- Aged 18 to ≤75 years at the time of informed consent.
Exclusion:
- Current Viral Infection (e.g. HBV, HCV, HIV, HTLV-1, HPVB19, syphilis, COVID- 19).
- Current low blood cell counts
- History of cancer, congenital malformations, or chromosomal abnormalities
- History of allergy to penicillin or streptomycin, or other serious allergies.
- Current poor medical condition, due to endocrine disease, metabolic disease, immune
disease, blood disease, psychiatric disorders, neurological diseases, cardiovascular
diseases, respiratory diseases, gastrointestinal diseases, musculoskeletal or
connective tissue diseases, renal or urogenital diseases.
- History of intracranial lesions, or stenosis, dissection or severe atherosclerotic
disease of a blood vessel in the head or neck.
- Current uncontrolled hypertension.
- Prior treatment with a cell or gene therapy.
- Currently participating in any other clinical trial.
- Women who are pregnant, breastfeeding, or plan to become pregnant during study
participation
- Men with plan for their partner to become pregnant during study participation.
Details
This study is a 69 week open label study of autologous bone-marrow-derived mesenchymal stem cells (STR04) in participants with ALS. Participants will undergo a screening visit, followed by collection of peripheral blood and bone marrow for the manufacture of STR04. Once manufacturing is successfully completed, participants will have a Baseline visit followed by 4 doses of STR04, one dose every 12 weeks. Participants will have a final assessments 12 weeks after the 4th dose.